Literature DB >> 23301534

Evaluation of antibiotic prescribing patterns in patients receiving sustained low-efficiency dialysis: opportunities for pharmacists.

Laura E Harris1, Anne B Reaves, Amy G Krauss, Justin Griner, Joanna Q Hudson.   

Abstract

OBJECTIVES: Sustained low-efficiency dialysis (SLED) is a 'hybrid' form of continuous renal replacement therapy; however, there is very limited information on drug disposition during this procedure. Individuals requiring SLED are often critically ill and require antibiotics. The study aim was to evaluate antibiotic orders for patients requiring SLED compared to literature-based recommendations. We also evaluated whether doses were administered as prescribed and assessed clinical and microbiologic cure.
METHODS: A retrospective review was performed over a 2-year period for patients who received concurrent SLED and antibiotic therapy. Demographic data, prescribed antibiotic dosing regimens and doses delivered as prescribed were determined for 10 antibiotics: cefepime (C), daptomycin (Da), doripenem (D), gentamicin (G), imipenem-cilastatin (I), linezolid (L), meropenem (M), piperacillin-tazobactam (P), tobramycin (T) and vancomycin (V). Dosing regimens were compared to recommendations from the literature where available. The incidence of clinical and microbiologic cure was also evaluated.
RESULTS: A total of 87 patients met inclusion criteria: mean age 54 ± 14 years, 60% male, 58% white. Prescribed doses were evidence-based for 37% of Da, 97% of L, 15% of M and 7% of V orders. The majority of discrepancies were due to under-dosing. There were 129 (11%) antibiotic doses missed. Of the 13 patients who met criteria for assessment of clinical and microbiologic cure, 10 achieved a microbiologic cure and none reached clinical cure.
CONCLUSIONS: Prescribed antibiotic dosing regimens varied substantially and under-dosing was common. There is a need to further define appropriate dosing regimens for antibiotics administered during SLED and determine how pharmacists may help to ensure appropriate therapy.
© 2012 The Authors. IJPP © 2012 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23301534     DOI: 10.1111/j.2042-7174.2012.00226.x

Source DB:  PubMed          Journal:  Int J Pharm Pract        ISSN: 0961-7671


  8 in total

1.  Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.

Authors:  Salmaan Kanji; Jason A Roberts; Jiao Xie; Sheryl Zelenitsky; Swapnil Hiremath; Guijun Zhang; Irene Watpool; Rebecca Porteous; Rakesh Patel
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

2.  Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.

Authors:  Leigh Anne Keough; Amy Krauss; Joanna Q Hudson
Journal:  Int J Clin Pharm       Date:  2018-07-26

Review 3.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06

4.  Survey of pharmacists’ antibiotic dosing recommendations for sustained low-efficiency dialysis.

Authors:  Jian P Mei; Azadeh Ali-Moghaddam; Bruce A Mueller
Journal:  Int J Clin Pharm       Date:  2016-02

5.  The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis.

Authors:  Andrzej Wieczorek; Andrzej Tokarz; Wojciech Gaszynski; Tomasz Gaszynski
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

6.  Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.

Authors:  Stephan Braune; Christina König; Jason A Roberts; Axel Nierhaus; Oliver Steinmetz; Michael Baehr; Stefan Kluge; Claudia Langebrake
Journal:  Crit Care       Date:  2018-01-30       Impact factor: 9.097

Review 7.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

8.  Vancomycin for Dialytic Therapy in Critically Ill Patients: Analysis of Its Reduction and the Factors Associated with Subtherapeutic Concentrations.

Authors:  Fernanda Moreira de Freitas; Welder Zamoner; Pamela Falbo Dos Reis; André Luís Balbi; Daniela Ponce
Journal:  Int J Environ Res Public Health       Date:  2020-09-19       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.